NVO - Ozempic Users Might Experience Caloric Intake Rise Post-Discontinuation: Survey | Benzinga
Deutsche Bank has recently conducted a survey suggesting that patients using Novo Nordisk A/S (NYSE:NVO) weight loss medication, Ozempic, may increase their caloric intake after discontinuing the treatment.
What Happened: The survey involved 600 U.S. consumers. Seventy percent of the participants were users of a GLP-1 drug like Ozempic or Wegovy, while 30% had discontinued such medication. The study revealed that calorie intake decreases while on the medication but increases once the patient stops the treatment. In some instances, caloric consumption is higher than before starting the treatment.
According to Dr. Shantanu Gaur, founder and CEO of Allurion Technologies Inc (NYSE:ALUR), “appetite can return with a vengeance” once patients cease GLP-1 therapy, reported CNBC.
Why It Matters: Novo Nordisk’s Wegovy has been linked to greater weight loss ...